Therapeuticsmd Inc (TXMD) Hedge Fund Ownership (Q2 2026)

Q: Is it too late to buy Therapeuticsmd Inc (TXMD) following the 2026 Q2 hedge fund 13F filings?

As of today, TXMD has moved -0.5% since the 2026 Q2 13F filing date (August 14, 2026), compared to +4.3% for the XLV sector ETF — an outperformance of -4.8%. Since the quarter end (June 30, 2026), TXMD gained -6.8% vs +10.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Therapeuticsmd Inc (TXMD)

44 + Investors. Track Smart Money conviction in TXMD. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — TXMD

Based on 45 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds added TXMD than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

45 hedge funds hold TXMD right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

📶

Steady growth — +15% more funds vs a year ago

fund count last 6Q

+6 new funds entered over the past year (+15% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.

🟡

Slight buying edge — 52% buying

17 buying16 selling

Last quarter: 17 funds bought or added vs 16 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

➡️

Steady new buyers — ~9 new funds per quarter

new funds entering per quarter

Funds opening this position for the first time: 4 → 5 → 5 → 9. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.

🔒

62% of holders stayed for 2+ years

■ 62% conviction (2yr+) ■ 22% medium ■ 16% new

28 out of 45 hedge funds have held TXMD for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💰

Value +42% but shares only +15% — price-driven

Value

+42%

+14%

Last quarter: the total dollar value of institutional holdings rose +42%, but actual share count only changed +15%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

➡️

Steady discovery — ~9 new funds/quarter

5 → 4 → 5 → 5 → 9 new funds/Q

New funds entering each quarter: 4 → 5 → 5 → 9. Consistent flow of new institutional buyers without clear acceleration or slowdown.

🏛️

Veteran-anchored — 67% veterans vs 22% newcomers

■ 67% veterans ■ 11% 1-2yr ■ 22% new

Entry-cohort mix of 46 holders: 31 (67%) are 2+ year veterans, 5 entered 1–2 years ago, and 10 (22%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

📋

Smaller funds dominant — 12% AUM from top-100

12% from top-100 AUM funds

11 of 44 holders rank in the top 100 by AUM, but together hold only 12% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

3.5

out of 10

Low Exit Risk

Exit risk score 3.5/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	44	45	-2.22%
13F Shares	4M	4M	-6.79%
Total Value	$8M	$8M	1.97%
New Positions	8	9	-1
Increased Positions	10	8	+2
Closed Positions	7	6	+1
Reduced Positions	7	9	-2
Total Calls	2	2	-
Total Puts	0	0	-
PUT/CALL Ratio	0.0	0.0	Bullish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

-2.22%

13F Shares

-6.79%

Total Value

$8M

1.97%

New Positions

-1

Increased Positions

Closed Positions

Reduced Positions

-2

Total Calls

Total Puts

PUT/CALL Ratio

0.0

Bullish

Institutional Holders (2026 Q2)

44 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in TXMD. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 TXMD holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Tejara Capital Ltd	0.31%	344,482	$761K
2	Clearline Capital LP	0.08%	635,222	$1.4M
3	ADAR1 Capital Management, LLC	0.03%	342,447	$757K
4	Rubric Capital Management LP	0.02%	1,192,191	$2.6M
5	Bridgeway Capital Management, LLC	0.00%	17,000	$38K
6	XTX Topco Ltd	0.00%	21,246	$47K
7	Renaissance Technologies LLC	0.00%	146,599	$324K
8	Tower Research Capital LLC (TRC)	0.00%	1,582	$3K
9	SBI Securities Co., Ltd.	0.00%	1,263	$3K
10	Hrt Financial LP	0.00%	14,727	$32K
11	Smartleaf Asset Management LLC	0.00%	601	$1K
12	Osaic Holdings, INC.	0.00%	15,198	$34K
13	Vanguard Fiduciary Trust Co	0.00%	63,831	$141K
14	Citadel Advisors LLC	0.00%	86,095	$190K
15	Atlatl Advisers LLC	0.00%	40	—
16	Activest Wealth Management	0.00%	40	—
17	Vanguard Capital Management LLC	0.00%	353,697	$782K
18	Morgan Stanley	0.00%	129,217	$286K
19	Provenance Wealth Advisors, LLC	0.00%	20	—
20	BlackRock, Inc.	0.00%	115,145	$254K
21	Truvestments Capital LLC	0.00%	10	—
22	Jane Street Group, LLC	0.00%	12,500	$28K
23	Susquehanna International Group, LLP	0.00%	13,100	$29K
24	Smallwood Wealth Investment Management, LLC	0.00%	2	—
25	UBS Group AG	0.00%	4,660	$10K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Therapeuticsmd Inc (TXMD)

What does the Smart Money Trend signal show for TXMD?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added TXMD than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for TXMD?

Slight buying edge — 52% buying: Last quarter: 17 funds bought or added vs 16 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for TXMD holders?

Smaller funds dominant — 12% AUM from top-100: 11 of 44 holders rank in the top 100 by AUM, but together hold only 12% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held TXMD?

62% of holders stayed for 2+ years: 28 out of 45 hedge funds have held TXMD for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Therapeuticsmd Inc (TXMD) following the 2026 Q2 hedge fund 13F filings?

As of today, TXMD has moved -0.5% since the 2026 Q2 13F filing date (August 14, 2026), compared to +4.3% for the XLV sector ETF — an outperformance of -4.8%. Since the quarter end (June 30, 2026), TXMD has gained -6.8% vs +10.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Therapeuticsmd Inc (TXMD)

Smart Money Signals — TXMD

Buying streak — 1 quarter in a row

At the ownership peak (100% of max)

Steady growth — +15% more funds vs a year ago

Slight buying edge — 52% buying

Steady new buyers — ~9 new funds per quarter

62% of holders stayed for 2+ years

Value +42% but shares only +15% — price-driven

Steady discovery — ~9 new funds/quarter

Veteran-anchored — 67% veterans vs 22% newcomers

Smaller funds dominant — 12% AUM from top-100

Institutional Sentiment Summary — TXMD

Hedge Fund Ownership: TXMD

Market Analysis: TXMD

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: TXMD

Is It Too Late to Buy Therapeuticsmd Inc (TXMD) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: TXMD

Statistics: TXMD

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Therapeuticsmd Inc (TXMD)

Welcome to 13Foresight!